<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36813250</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>20</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0260</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><PubDate><Year>2023</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Preventive medicine</Title><ISOAbbreviation>Prev Med</ISOAbbreviation></Journal><ArticleTitle>The prevalence of SARS-CoV-2 infection and long COVID in U.S. adults during the BA.4/BA.5 surge, June-July 2022.</ArticleTitle><Pagination><StartPage>107461</StartPage><MedlinePgn>107461</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ypmed.2023.107461</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0091-7435(23)00041-5</ELocationID><Abstract><AbstractText>Due to changes in SARS-CoV-2 testing practices, passive case-based surveillance may be an increasingly unreliable indicator for monitoring the burden of SARS-CoV-2, especially during surges. We conducted a cross-sectional survey of a population-representative sample of 3042&#xa0;U.S. adults between June 30 and July 2, 2022, during the Omicron BA.4/BA.5 surge. Respondents were asked about SARS-CoV-2 testing and outcomes, COVID-like symptoms, contact with cases, and experience with prolonged COVID-19 symptoms following prior infection. We estimated the weighted age and sex-standardized SARS-CoV-2 prevalence, during the 14-day period preceding the interview. We estimated age and gender adjusted prevalence ratios (aPR) for current SARS-CoV-2 infection using a log-binomial regression model. An estimated 17.3% (95% CI 14.9, 19.8) of respondents had SARS-CoV-2 infection during the two-week study period-equating to 44 million cases as compared to 1.8 million per the CDC during the same time period. SARS-CoV-2 prevalence was higher among those 18-24&#xa0;years old (aPR 2.2, 95% CI 1.8, 2.7) and among non-Hispanic Black (aPR 1.7, 95% CI 1.4,2.2) and Hispanic adults (aPR 2.4, 95% CI 2.0, 2.9). SARS-CoV-2 prevalence was also higher among those with lower income (aPR 1.9, 95% CI 1.5, 2.3), lower education (aPR 3.7 95% CI 3.0,4.7), and those with comorbidities (aPR 1.6, 95% CI 1.4, 2.0). An estimated 21.5% (95% CI 18.2, 24.7) of respondents with a SARS-CoV-2 infection &gt;4&#xa0;weeks prior reported long COVID symptoms. The inequitable distribution of SARS-CoV-2 prevalence during the BA.4/BA.5 surge will likely drive inequities in the future burden of long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qasmieh</LastName><ForeName>Saba A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>McKaylee M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teasdale</LastName><ForeName>Chloe A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Sarah G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Heidi E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McNairy</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA; Center for Global Health and Division of General Internal Medicine, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrell</LastName><ForeName>Luisa N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nash</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, NY, USA; Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, NY, USA. Electronic address: denis.nash@sph.cuny.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prev Med</MedlineTA><NlmUniqueID>0322116</NlmUniqueID><ISSNLinking>0091-7435</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Population-based surveys</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Surveillance</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>19</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36813250</ArticleId><ArticleId IdType="pmc">PMC9940463</ArticleId><ArticleId IdType="doi">10.1016/j.ypmed.2023.107461</ArticleId><ArticleId IdType="pii">S0091-7435(23)00041-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Ayoub H.H., et al. Effect of mRNA vaccine boosters against SARS-CoV-2 omicron infection in Qatar. N. Engl. J. Med. 2022;386(19):1804&#x2013;1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929389</ArticleId><ArticleId IdType="pubmed">35263534</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucau J., Marino C., Regan J., et al. Duration of shedding of culturable virus in SARS-CoV-2 omicron (BA.1) infection. N. Engl. J. Med. 2022 doi: 10.1056/NEJMc2202092. Published online June 29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2202092</ArticleId><ArticleId IdType="pmc">PMC9258747</ArticleId><ArticleId IdType="pubmed">35767428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L., Baca S., Saydah S., et al. Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years &#x2014; United States, march 2020&#x2013;November 2021. MMWR Surveill. Summ. 2022;71(21):713.</Citation></Reference><Reference><Citation>CDC . Antibody Seroprevalence. Centers for Disease Control and Prevention; 2020. COVID data tracker.https://covid.cdc.gov/covid-data-tracker/#trends_dailycases_select_00 Published March 28. Accessed August 27, 2022.</Citation></Reference><Reference><Citation>CDC . Variants &amp; Genomic Surveillance. Centers for Disease Control and Prevention; 2020. COVID data tracker.https://covid.cdc.gov/covid-data-tracker/#variant-proportions Published March 28, 2020. Accessed July 19, 2022.</Citation></Reference><Reference><Citation>CDC . Centers for Disease Control and Prevention; 2020. COVID data tracker. Cases, Deaths, &amp; Testing.https://covid.cdc.gov/covid-data-tracker/#trends_dailycases_select_00 Published March 28, 2020. Accessed August 27, 2022.</Citation></Reference><Reference><Citation>Clarke K.E.N., Jones J.M., Deng Y., et al. Seroprevalence of infection-induced SARS-CoV-2 antibodies &#x2014; United States, September 2021&#x2013;February 2022. MMWR Morb. Mortal. Wkly Rep. 2022;71(17):606&#x2013;608. doi: 10.15585/mmwr.mm7117e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7117e3</ArticleId><ArticleId IdType="pmc">PMC9098232</ArticleId><ArticleId IdType="pubmed">35482574</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19) Infection Survey: methods and further information. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19infectionsurveypilotmethodsandfurtherinformation Accessed August 23, 2022.</Citation></Reference><Reference><Citation>CSTE Interim Position Statement: Update to COVID-19 Case Definition - Council of State and Territorial Epidemiologists. https://www.cste.org/news/520707/CSTE-Interim-Position-Statement-Update-to-COVID-19-Case-Definition.htm Accessed April 23, 2022.</Citation></Reference><Reference><Citation>Dean N. Tracking COVID-19 infections: time for change. Nature. 2022;602(7896):185.</Citation><ArticleIdList><ArticleId IdType="pubmed">35136224</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.A.W., DeCuir J., Coyle J.P., et al. COVID-19 case surveillance: trends in person-level case data completeness, United States, April 5&#x2013;September 30, 2020. Public Health Rep. 2021;136(4):466&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8203037</ArticleId><ArticleId IdType="pubmed">33789540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones J.M., Opsomer J.D., Stone M., et al. Updated US infection- and vaccine-induced SARS-CoV-2 seroprevalence estimates based on blood donations, July 2020-December 2021. JAMA. 2022;328(3):298&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9194752</ArticleId><ArticleId IdType="pubmed">35696249</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaim A., Saban M. Are we suffering from the Peltzman effect? Risk perception among recovered and vaccinated people during the COVID-19 pandemic in Israel. Public Health. 2022;209:19&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9156958</ArticleId><ArticleId IdType="pubmed">35777089</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefferts B., Blake I., Bruden D., et al. Antigen test positivity after COVID-19 isolation - Yukon-Kuskokwim Delta region, Alaska, January-February 2022. MMWR Morb. Mortal. Wkly Rep. 2022;71(8):293&#x2013;298.</Citation><ArticleIdList><ArticleId IdType="pubmed">35202352</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R., Levy M.E., Gaglani M., et al. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated &#x2014; VISION Network, 10 States, December 2021&#x2013;June 2022. MMWR Morb. Mortal. Wkly Rep. 2022;71(29):931&#x2013;939. doi: 10.15585/mmwr.mm7129e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7129e1</ArticleId><ArticleId IdType="pmc">PMC9310634</ArticleId><ArticleId IdType="pubmed">35862287</ArticleId></ArticleIdList></Reference><Reference><Citation>Long COVID https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm Published July 19, 2022. Accessed August 12, 2022.</Citation></Reference><Reference><Citation>Ma Q., Liu J., Liu Q., et al. Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: a systematic review and Meta-analysis. JAMA Netw. Open. 2021;4(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8672238</ArticleId><ArticleId IdType="pubmed">34905008</ArticleId></ArticleIdList></Reference><Reference><Citation>Nash D., Geng E. Goal-aligned, epidemic intelligence for the public health response to the COVID-19 pandemic. Am. J. Public Health. 2020;110(8):1154&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349456</ArticleId><ArticleId IdType="pubmed">32614614</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis R.H., Santillana M., Ognyanova K., et al. Prevalence and correlates of Long COVID symptoms among US adults. JAMA Netw. Open. 2022;5(10)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9614581</ArticleId><ArticleId IdType="pubmed">36301542</ArticleId></ArticleIdList></Reference><Reference><Citation>Qasmieh S.A., Robertson M.M., Teasdale C.A., Kulkarni S.G., Nash D. 2022. Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022. Published online April 27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.04.23.22274214</ArticleId><ArticleId IdType="pmc">PMC9384757</ArticleId><ArticleId IdType="pubmed">35959571</ArticleId></ArticleIdList></Reference><Reference><Citation>Qasmieh SA, Robertson MM, Teasdale CA, Kulkarni SG, Nash D. Estimating the period prevalence of SARS-CoV-2 infection during the Omicron (BA.1) surge in New York City (NYC), January 1-March 16, 2022. Clin. Infect. Dis.. Published online August 12, 2022b. doi:10.1093/cid/ciac644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac644</ArticleId><ArticleId IdType="pmc">PMC9384757</ArticleId><ArticleId IdType="pubmed">35959571</ArticleId></ArticleIdList></Reference><Reference><Citation>Qasmieh S.A., Robertson M.M., Teasdale C.A., et al. The prevalence of SARS-CoV-2 infection and other public health outcomes during the BA.2/BA.2.12.1 surge, New York City, April&#x2013;May 2022. bioRxiv. 2022 doi: 10.1101/2022.05.25.22275603. Published online May 26, 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.25.22275603</ArticleId><ArticleId IdType="pmc">PMC10313770</ArticleId><ArticleId IdType="pubmed">37391483</ArticleId></ArticleIdList></Reference><Reference><Citation>Rader B., Gertz A., Iuliano A.D., et al. Use of at-home COVID-19 tests - United States, august 23, 2021-march 12, 2022. MMWR Morb. Mortal. Wkly Rep. 2022;71(13):489&#x2013;494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8979595</ArticleId><ArticleId IdType="pubmed">35358168</ArticleId></ArticleIdList></Reference><Reference><Citation>Rane M.S., Profeta A., Poehlein E., et al. SARS-CoV-2 pandemic in New York metropolitan area: the view from a major urgent care provider. Ann. Epidemiol. 2022 doi: 10.1016/j.annepidem.2022.05.006. Published online June 2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annepidem.2022.05.006</ArticleId><ArticleId IdType="pmc">PMC9159971</ArticleId><ArticleId IdType="pubmed">35660641</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie, Mathieu, Rod&#xe9;s-Guirao, et al. Coronavirus Pandemic (COVID-19). Our World in Data. https://ourworldindata.org/covid-vaccinations.</Citation></Reference><Reference><Citation>Robertson M.M., Shamsunder M.G., Brazier E., et al. Racial/ethnic disparities in exposure, disease susceptibility, and clinical outcomes during COVID-19 pandemic in national cohort of adults, United States. Emerg. Infect. Dis. 2022;28(11):2171&#x2013;2180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9622253</ArticleId><ArticleId IdType="pubmed">36191624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherratt K., Abbott S., Meakin S.R., et al. Exploring surveillance data biases when estimating the reproduction number: with insights into subpopulation transmission of COVID-19 in England. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 1829;2021(376):20200283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8165604</ArticleId><ArticleId IdType="pubmed">34053260</ArticleId></ArticleIdList></Reference><Reference><Citation>Shircliff E.J., Rosenberg E.S., Collens L.M., et al.  Notes from the Field School-Based and Laboratory-Based Reporting of Positive COVID-19 Test Results among School-Aged Children -New York, September 11, 2021-April 29, 2022. https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7132a2-H.pdf Accessed January 3, 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400535</ArticleId><ArticleId IdType="pubmed">35951493</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson R.B., Lauren B.N., Schipper K.H., McCann J.C., Tarnas M.C., Naumova E.N. Critical periods, critical time points and day-of-the-week effects in COVID-19 surveillance data: an example in Middlesex County, Massachusetts, USA. Int. J. Environ. Res. Public Health. 2022;vol. 19(3) doi: 10.3390/ijerph19031321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19031321</ArticleId><ArticleId IdType="pmc">PMC8835321</ArticleId><ArticleId IdType="pubmed">35162344</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28(8):1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson E.J., Williams D.M., Walker A.J., et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat. Commun. 2022;13(1):3528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Census Bureau QuickFacts: United States. https://www.census.gov/quickfacts/fact/table/US/PST045221 Accessed August 2, 2022.</Citation></Reference><Reference><Citation>Walgreens COVID-19 index Walgreens. https://www.walgreens.com/businesssolutions/covid-19-index.jsp Accessed August 24, 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>